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Abstract
Background: 
Introduction:  The aim of this study was to evaluate a simple diagnostic test for Gilbert's
syndrome (GS), which avoids hospitalization and exposure to toxic test substrates. GS is the most
frequent cause of isolated unconjugated hyperbilirubinemia. The nicotinic acid test and the starving
test are established approaches to diagnose GS. However, these tests cause considerable side
effects or require hospital admission. In single GS patients, we observed rapid serum bilirubin
normalization after a standard European lunch (the "inverse starving test").
Findings: At two consecutive days, 18 profoundly characterized GS patients (7 females, 11 males,
median age 34.5 years, range 21–58 years) were investigated with the nicotinic acid test and the
inverse starving test. Unconjugated serum bilirubin (UCB) levels were measured before and hourly
up to four hours after lunch (median 645 kcal), and after the ingestion of 170 milligrams nicotinic
acid, respectively. Patients who consulted their physicians with jaundice were significantly more
likely to undergo invasive diagnostic procedures than patients with an incidental finding of elevated
UCB, despite UCB levels were indifferent in both groups. Two hours after nicotinic acid ingestion,
relative UCB exceeded 1.7 fold the fasting levels (median, range 0.9–2.4 fold, sensitivity 83%). In
the inverse starving test, UCB remained almost unchanged three hours after lunch (median 1.0;
range: 0.8–1.2 fold). Molecular analysis established the genotype of the TATAA box of the UGT1A1
gene; all patients carried an UGT1A1 promotor polymorphism.
Conclusion: The inverse starving test is not an appropriate provocation test for patients with
suspected GS. The 100% prevalence of the UGT1A1 polymorphism in our cohort underlines that
the diagnosis of GS may be substantiated with this simple molecular test in patients with an
uncertain diagnosis of GS.
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Findings
Background
Conjugation with glucuronic acid is essential for efficient
excretion of bilirubin. Bilirubin glucuronidation is medi-
ated by a microsomal enzyme, the bilirubin uridine
diphosphate glucuronosyltransferase (UGT1A1; EC
2.4.1.17) [1]. Gilbert's syndrome (syn. icterus juvenilis
Meulengracht) is an inherited benign disorder character-
ized by unconjugated hyperbilirubinemia in the absence
of structural liver disease or haemolysis [2]. The elevated
unconjugated bilirubin (UCB) concentration is usually
noted first in adolescence, either as an incidental finding
or because of a slight yellow discoloration of the sclera.
The serum bilirubin concentration characteristically fluc-
tuates daily, occasionally falling within the normal range.
During fasting, physical exercise, stress, intercurrent ill-
ness, or menstruation bilirubin exceeds the upper normal
limit, sometimes by as much as four times. Gilbert's syn-
drome only occasionally causes critical symptoms, if treat-
ment with cytostatic drugs as irinotecan is necessary. In
these circumstances, live threatening complications as
grade 4 neutropenia and diarrhoea may occur [3,4]. Fur-
thermore, patients with a UGT1A1  promoter polymor-
phism are more likely to develop hyperbilirubinemia after
treatment with the anti-retroviral protease inhibitor ata-
zanavir [5].
GS prevalence ranges from 2% to 12% in different popu-
lations [6,7]. The inheritance of GS is either autosomal
dominant with an incomplete penetrance or recessive. A
promotor polymorphism of the TATAA box within the
UGT1A1 gene is associated with GS in more than 50% of
patients [8].
The clinical diagnosis of Gilbert's syndrome is made by
exclusion of liver disease or overt haemolysis. Several
provocation tests have been established to discriminate
GS patients from patients with acute or chronic liver dis-
ease, haemolytic anemia and healthy volunteers.
The "caloric restriction" or "starving" test has been inau-
gurated by Augustine Gilbert itself [9]. It involves restrict-
ing the caloric intake to 400 kcal per 24 h for two days.
This should double UCB from the baseline level and
clearly distinct GS patients from healthy volunteers [10].
The discrimination from non-GS patients was insufficient,
however, if patients with liver cirrhosis or acute hepatitis
have been compared with GS patients [11,12]. Moreover,
this test is time-consuming and requires hospital admis-
sion to control blood glucose levels and the exact caloric
intake throughout the test period. Moreover, an evalua-
tion for the presence of GS fails the "Appropriateness Eval-
uation Protocol" (AEP) criteria of admission to hospitals
and is not reimbursed by the public health insurances in
Germany.
The  nicotinic acid test involves overnight fasting and
intravenous (50 mg) or oral (170 – 300 mg) administra-
tion of nicotinic acid (NA) [13,14]. A significant increase
of UCB is seen in GS patients. The most frequent adverse
event of nicotinic acid is vasodilatation. It is frequently
accompanied with tachycardia, headache, nausea and
vomiting. Another adverse event is haemolysis, which is
probably caused by a higher susceptibility of erythrocytes
to splenic haemolysis, since the NA triggered UCB rise is
abolished after splenectomy [15,16]. In a small series,
indomethacin pre-treatment was able to reduce NA side
effects without changing the hyperbilirubinemic effect of
nicotinic acid [17]. All studies, which directly compared
the starving test and the intravenous nicotinic acid test
found a higher bilirubin increase in the latter [10,17].
Rifampin  induces cytochrome P-450 isoenzymes and
competes for the excretory pathways in liver cells. The
"rifampin test" with 900 mg orally administered rifampin
had the ability to distinguish GS patients from controls in
one pilot study [18]. Actually, Hallal and colleagues con-
firmed the usefulness of the rifampin test in a study with
89 GS patients and pointed to the better diagnostic value
of the relative rather than the absolute bilirubin increase
after rifampin administration [19]. In both studies, con-
flicting findings regarding rifampin induced haemolysis
were reported. Furthermore, both studies did not report
on the frequency of adverse events after rifampin admin-
istration, such as heartburn, vomiting or even hepatitis. As
well, severe complications such as disseminated intravas-
cular coagulation or serious hypersensitivity reactions
including the Stevens-Johnson Syndrome and toxic epi-
dermal necrolysis may rarely occur after rifampin admin-
istration.
The aim of this study was to evaluate a simple diagnostic
test for GS, which avoids hospitalization and exposure to
toxic test substrates. Single case observations revealed a
rapid decline of UCB in overnight fasting GS patients, if
they have ingested a standard European lunch. This
approach is inexpensive, non-toxic and practicable in an
out-patients department. Deriving from these observa-
tions, we conducted this prospective study to evaluate the
diagnostic accuracy of this "inverse starving test" in
patients with GS. The test was pre-assigned to be clinical
useful, if an UCB-decline of at least 50% could be
achieved. So far, no gold standard for the diagnosis of GS
has been established. As a reasonable control investiga-
tion, we used the nicotinic acid test, which should
increase UCB by 50%.
Methods
Between July and November 2006, we sent invitation let-
ters to 59 patients with (suspected) GS. After comprehen-
sive information, 20 patients matched the inclusionBMC Research Notes 2008, 1:35 http://www.biomedcentral.com/1756-0500/1/35
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criteria and gave their written informed consent. Two
patients were excluded from the study, as they matched a
stop criterion: One 28-year-old male with remittent ulcer-
ative colitis had a haptoglobin level <0,2 due to a so far
unknown slight haemolysis (haemoglobin concentration
= 7.6 mmol/L, normal range 8.2–10.7; lactate dehydroge-
nase 3.82 microkat/l, normal range 2.25–3.75). A 50-
year-old female was excluded due to a liver nodule of 1
centimetre. Invasive diagnostics and a six months follow-
up did not reveale malignancy so far. Furthermore, one
32-year-old female declined to continue the study after
the sonographic finding of a fatty liver.
The diagnosis of GS was suspected at least three months
before our investigation due to elevated unconjugated
bilirubin levels, normal aspartate amino transferase
(ASAT, GOT), alanine amino transferase (ALAT, GPT),
gamma-glutamyl transferase (GGT), alkaline phos-
phatase, lactate dehydrogenase (LDH) and haptoglobine
levels. Molecular analysis established the genotype of the
TATAA box of the UGT1A1 gene by standard molecular
techniques; all patients carried an UGT1A1 promotor pol-
ymorphism. The study was approved by the Ethics Com-
mittee of the University of Leipzig. This committee did
not consent to expand our investigations to healthy con-
trols. Exclusion and stop criteria are referred in the tables
1 and 2.
The inverse starving test required an overnight fast. On
arrival in the out-patients department, an initial blood
sampling for conjugated and unconjugated bilirubin,
ALAT, ASAT, GGT, lactate dehydrogenase, alkaline phos-
phatase and haptoglobine was done via an intravenous
catheter. Within the next two hours, an abdominal ultra-
sound was carried out to exclude focal liver lesions and
mechanic cholestasis. Two patients with abnormal find-
ings in these investigations had to be excluded and were
advised to undergo further diagnostics. 18 Patients with-
out exclusion criteria got a free lunch of choice in the uni-
versity restaurant after a second fasting blood sample was
taken directly before lunch. After lunch, blood samples for
bilirubin analysis were taken hourly up to 4 hours.
The nicotinic acid test was performed at the next day.
After an overnight fast and fasting UCB analysis, the
patients ingested 170 mg nicotinic acid with pure water.
Further blood samples were taken in hourly intervals up
to 4 hours. Between the repeated blood drawings via an
intravenous catheter, the patients were advised to rest in
the waiting room, and were only allowed to drink pure
water.
Statistical Analysis
All results were evaluated as median (interquartile range
(IQR)) for continuous variables, and frequency counts for
categorical variables. According to earlier publications a
reduction greater than 1.5 relative UCB in starving test or
an increase greater than 1.5 UCB in nicotinic acid test
were assessed as clinical relevant. A sensitivity analysis
was performed for all tests and time points.
Results
18 GS patients completed both tests at two consecutive
days. These included 11 males and 7 females with a
median age of 34.5 years (range, 21–58), and a median
body mass index of 22.1 kg/m2 (range, 21.5–24). Two
Table 1: Exclusion criteria
Exclusion criteria
nicotine incompatibility
history of haemolysis
history of myocardial infarction, coronary artery disease, cardiac arrhythmia or angina pectoris
Hyperthyroidism
pheochromocytoma
insulin dependent diabetes mellitus
arterial hypertension
kidney- or liver disease
patient's age under 18 or over 60 years
pregnancy and lactation
simultaneous participation in other clinical studies
Table 2: Stop criteria
Stop criteria
Solid liver lesion (other than typical cysts) or mechanic cholestasis in sonography
Elevated GOT, GPT, AP, GGTBMC Research Notes 2008, 1:35 http://www.biomedcentral.com/1756-0500/1/35
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patients smoked 10 or 15 cigarettes per day, respectively,
whereas the others were non-smokers. No patient regu-
larly drinks alcohol, and none drunk alcohol within 24
hours before the tests and at the test days. None of the
females used hormonal contraceptives. No patient had
fever or felt unwell within one month before the tests.
The test patients had different initial symptoms. Yellow
eyes (one with coincidental yellow skin) were noticed by
three patients by themselves and in five cases by a relative.
Fatigue was the first symptom in one case. In the remain-
ing nine, elevated bilirubin levels were an incidental lab-
oratory finding. The eight patients who consulted their
doctors due to jaundice were significantly more likely to
undergo liver biopsy (n = 4) or endoscopic retrograde
cholangio-pancreaticography (ERCP, n = 1) than the nine
patients with an incidental finding of elevated UCB (n =
0, p = 0.038, fisher exact test). Interestingly, fasting UCB
was not different between these groups (p > 0.3, t-test).
Previously, all patients had ultrasound examinations; a
computed tomography was done in three patients and
magnet resonance tomography in two cases. Fasting UCB
was not different between the patients who have under-
gone extensive radiological diagnostics and the patients
with ultrasound only (p > 0.5). Bone marrow examina-
tion was not carried out in any case.
The inverse starving test
The median starving time between last caloric intake at
the day before this test and the lunch of choice in the uni-
versity restaurant was 15:30 hours (range: 13:30–17:15
hours). Side effects were recognized in two patients (table
3). As shown in figure 1, the inverse starving test induced
an UCB reduction to normal range (<15.4 μmol/L) or a
relative UCB reduction of more than 50% in none of the
patients. Box plot analysis revealed only a negligible
decrease in UCB levels over the test period (figure 2). We
hypothesized that the UCB decline after lunch should be
mutually dependent from caloric intake, but no correla-
tion could be detected (Figures 2 and 3).
The nicotinic acid test
Basal UCB at day 2 (nicotinic acid test) were almost iden-
tical (p = 0.88, t-test) with day 1 (inverse starving test).
Two hours after ingestion of 170 milligrams NA, UCB was
elevated > 50% in 15 of the 18 patients (sensitivity 83%,
figure 4). Box plot analysis showed the typical course of
nicotinic acid test with a precise discrimination of the rel-
ative UCB from the baseline value (figure 2). NA side
effects were recognized in 16 patients (table 4). The con-
jugated bilirubin levels did not change during both tests
(data not shown).
Discussion
The "inverse starving test" was not able to induce a more
than 50% reduction of UCB in our patients with GS. We
conclude that this test is not a useful provocation test for
GS. As previously reported using intravenous protocols
for the nicotinic acid test, the oral ingestion of 170 mg nic-
otinic acid failed to induce an UCB increase > 50% in 3 of
our 18 test persons with GS, which results in a sensitivity
UCB course in the inverse starving test in the 19 test subjects. Figure 1
UCB course in the inverse starving test in the 19 test subjects. The normal range (15.4 μmol/L) was indicated in grey.BMC Research Notes 2008, 1:35 http://www.biomedcentral.com/1756-0500/1/35
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Relative UCB change in nicotinic acid test (solid boxes) and inverse starving test (open boxes) (dotted line indicated the base- line value) Figure 2
Relative UCB change in nicotinic acid test (solid boxes) and inverse starving test (open boxes) (dotted line indicated the base-
line value).
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of only 83%. Confirming previous findings, this UCB
increase was less intensive with the oral than with the
intravenous approach, respectively [10,11,18-20].
One potential cause of the failure of our procedure ist,
that the inverse starving test was started after only one
overnight fast and a number of bilirubin baseline levels
were just above normal. In the classic caloric restriction
test, h owever, best specificity and sensitivity was achieved
after 48 hours [21-23]. It might be speculated therefore,
that 48 hours of restricted calorie intake might induce
higher baseline bilirubin levels and improve the results of
the inverse starving test. However, it was not our aim to
introduce another cumbersome and unpleasant proce-
dure to investigate patients for the GS.
Due to a lack of international standards in the evaluation
of patients with UCB elevations, patients usually undergo
very different investigations to find out the diagnosis of
Gilbert's syndrome. In our cohort, patients who consulted
their physicians with jaundice were significantly more
likely to undergo invasive diagnostic procedures than
patients with an incidental finding of elevated UCB. As
the median UCB did not differ in these groups, the doc-
tor's decision for an invasive approach seems to be driven
by the patient's demand for a diagnosis but not by a sub-
stantiated scientific approach.
In conclusion, the inverse starving test is not an appropri-
ate provocation test for patients with suspected GS. Today,
no international gold standard exists for the diagnostic
criteria of GS and protocols for the nicotinic acid test are
differing in a broad range of its test conditions. Due to its
unsatisfying sensitivity and its considerable adverse
effects, the nicotinic acid test seems not to be mandatory
for the GS diagnosis. A growing number of authors sug-
gest that there is no need for provocation tests at all, if no
change in the typical laboratory constellation of an iso-
lated UCB elevation occurred after 3–6 months. In agree-
ment with this, we suggest that the clinical diagnosis of GS
can be established in patients with a high fraction of UCB,
normal values of liver enzymes and no laboratory signs of
haemolysis at the time of the initial consultation and
three months later.
Table 3: Adverse events of the inverse starving test
Adverse events of the inverse starving test
1 pt. headache at the evening of the test day
1 pt. vomiting at the afternoon and evening of the test day
UCB course in the nicotinic acid test in the 19 test subjects. Figure 4
UCB course in the nicotinic acid test in the 19 test subjects. The normal range (15.4 μmol/L) was indicated in grey.Publish with BioMed Central    and   every 
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